BLRX
BioLineRx Ltd.
NASDAQ · Healthcare · Biotechnology · IL
$1.98
−2.23%Oct 23, 2026, 11:00 UTC
BioLineRx Ltd. and Hemispherian AS presented preclinical data at ESMO 2026 showing synergy between GLIX1 and multiple PARP inhibitors in HR-proficient ovarian cancer models.
Source:Aug 31, 2026, 11:00 UTC
BioLineRx reported its unaudited financial results for the quarter ended June 30, 2026, and provided a corporate update.
Source:Aug 28, 2026, 12:00 UTC
BioLineRx Ltd. announced a registered direct offering and concurrent private placement of 1,348,921 American Depositary Shares at $2.78 per ADS, raising approximately $3.75 million.
Source: